Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Down 7.11%
As of Tuesday, September 29, Unicycive Therapeutics, Inc.’s UNCY share price has dipped by 7.11%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. UNCY
$4.55
-0.15
-3.09%
October 1, 2026 4:00:00 PM
EST
Volume: 1,046,094
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Commentary & Analysis
Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Down 5.44%
As of Tuesday, September 15, Unicycive Therapeutics, Inc.’s UNCY share price has dipped by 5.44%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Down 5.33%
As of Monday, August 24, Unicycive Therapeutics, Inc.’s UNCY share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Up 5.62%
As of Wednesday, August 12, Unicycive Therapeutics, Inc.’s UNCY share price has surged by 5.62%, which has investors questioning if this is right time to sell.Michael Rose
Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Down 6.04%
As of Friday, July 31, Unicycive Therapeutics, Inc.’s UNCY share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | UNCY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $126.7 | $250.6 | 24% |
|
| Shares Out (Mil) | 26.9 | 54.0 | 35% |
|
| Institutional Ownership | 94.6% | 93.1% | 65% |
|
| Float (Mil) | 27.2 | 41.4 | 34% |
|
| Beta | 1.78 | 0.95 | 88% |
|
| Avg Daily Volume (000s) | 888 | 720 | 66% |
|
| Price Change (52-week) |
4.4% | 49.4% | 57% |
|
| Growth | UNCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (63.2%) | (10.2%) | 5% |
|
| EPS (5yr) | 8.9% | 15.7% | 45 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 63.0% | (15.7%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 8 | |
| Current EPS | ($0.351) | ($1.266) | $1.686 | |
| Month Ago EPS | ($0.352) | ($1.229) | $1.663 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.364) | ($1.498) | $5.104 | |
| Year/Year Chg | 448.4% | (24.3%) | (614.1%) | |
| Financials | UNCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $36 | na |
|
| Net Income (TTM) (Mil) | ($35) | ($44) | 19% |
|
| EPS (TTM) | ($1.559) | ($1.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($28) | ($33) | 13% |
|
| Net Cash Flow (TTM) (Mil) | $22 | $2 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $89 | $174 | 20% |
|
| Valuation | UNCY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.38 | 2.41 | 59% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | UNCY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (69.0%) | (47.7%) | 9% |
|
| ROE | (101.1%) | (55.0%) | 9% |
|
| Liabilities to Assets | 26.0% | 29.3% | 18% |
|
| F-Score | 3 | 3 | 18% |
|
Unicycive Therapeutics, Inc. did not pass any screens on 10/1/2026.
